Navigation Links
Biotel Announces Profitable Second Quarter Ended December 31, 2008

MINNEAPOLIS, Feb. 12 /PRNewswire-FirstCall/ -- Biotel Inc. (OTC Bulletin Board: BTEL) announced results for its second quarter ended December 31, 2008, with net earnings of $289,000, or $0.10 per diluted share, on revenues of $3,186,000. This compares to net earnings of $206,000, or $0.07 per diluted share, on revenues of $2,859,000 for the second quarter of last year. For the six months ended December 31, 2008, Biotel had net earnings of $617,000, or $0.22 per diluted share, on revenues of $6,354,000. This compares to net earnings of $376,000, or $0.13 per diluted share, on revenues of $5,610.000 for the first six months of last year.

    Highlights for the second quarter are as follows:

    * Ninth consecutive profitable quarter
    * Net income up 40.3% year over year
    * Strong gross margin of 45.9%, versus 44.7% a year ago
    * Strong balance sheet with no long-term bank debt
    * Stockholders' equity of $5,320,000, up 22.8% year over year

"We are pleased with Biotel's revenue growth, margin improvement and overall performance in the second quarter," Biotel President and CEO Steve Springrose said. "Sales of the Braemar ER920W wireless arrhythmia monitor remained strong as one of our OEM partners continued ordering product for inventory stocking. We expect sales to this customer to diminish in the second half. Sales of Braemar Holter devices, event recorders, liposuction equipment and other medical devices remained solid. Having received FDA 510(k) approval of our Fusion platform of wireless ECG monitoring products, we are beginning shipments of an evaluation version of the product this quarter, followed by a planned limited clinical release and distribution of Fusion products in our fourth quarter. Biotel serves as a development partner to medical corporations seeking new devices and clinical research services."

                               3 months ended  3 months ended
                                 December 31,    December 31,         %
                                     2008            2007           Change

    Revenues                     $3,186,000      $2,859,000         11.4%
    Net Income                     $289,000        $206,000         40.3%
    Earnings Per Share, Basic         $0.10           $0.08
    Earnings Per Share, Diluted       $0.10           $0.07

                               6 months ended  6 months ended
                                 December 31,    December 31,         %
                                     2008            2007           Change

    Revenues                     $6,354,000      $5,610,000         13.3%
    Net Income                     $617,000        $376,000         64.2%
    Earnings Per Share, Basic         $0.22           $0.14
    Earnings Per Share, Diluted       $0.22           $0.13

SOURCE Biotel Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biotel Announces Profitable Third Quarter Ended March 31, 2008
2. Biotel Announces Strong Results for the Second Quarter Ended December 31, 2007
3. Biotel Announces Strong Results for the First Quarter Ended September 30, 2007, FDA 510(k) Clearance for the Braemar ER900 Wireless Event Recorder
4. Biotel Announces Record Revenues and Strong Earnings for the Fourth Quarter and Year Ended June 30, 2007
5. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
6. Investor Group Commends Jim Merselis for Joining Trinity Biotechs Board of Directors & Announces Conference Call Invitation
7. Cogdell Spencer Announces Dorr as President of the Southeast Region
8. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
9. Terri Lynne Lokoff Child Care Foundation Announces Recipients of the 2009 Terri Lynne Lokoff/Childrens TYLENOL(R) National Child Care Teacher Awards(TM)
10. Webinar Alert: Coverity Announces Verification and Validation of Medical Device Software with Static Analysis - A Review of FDA Guidance and Best Practices
11. Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: